Focus: Gedeon Richter is a 125-year-old Hungarian public pharmaceutical company with 1,001–5,000 employees focused on small molecules and generics across neurology, cardiovascular, metabolic, and immunology indications. The company operates as a mid-cap generics and specialty pharma player with an established commercial footprint in Central/Eastern Europe and expanding global reach.
Profile data last refreshed 15h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Gedeon Richter to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Gedeon Richter's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Calcium-channel blocker ANDA product in pre-launch phase targeting core cardiovascular indication; represents entry into high-volume generic antihypertensive market.
Help build intelligence for Gedeon Richter
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Broad-spectrum azole antifungal in pre-launch ANDA; addresses established infectious disease indication with stable demand.
Allylamine antifungal in pre-launch phase; complements antifungal portfolio with dermatological and systemic fungal coverage.
Mature generic post-LOE facing commodity competition; low-margin urology staple sustaining base revenue but offering limited growth.
Richter Gedeon Nyrt. stock (HU0000123096): shares steady as Budapest pharma name digests recent divi - AD HOC NEWS
Richter Gedeon Nyrt. stock (HU0000123096): shares steady as Budapest pharma name digests recent divi AD HOC NEWS
Richter Gedeon stock (HU0000123096): Drugmaker updates investors after recent company news - AD HOC NEWS
Richter Gedeon stock (HU0000123096): Drugmaker updates investors after recent company news AD HOC NEWS
Richter Expands Rheumatology Portfolio with EU-Approved Medicine - Hungary Today
Richter Expands Rheumatology Portfolio with EU-Approved Medicine Hungary Today
Richter Gedeon Nyrt. Stock (HU0000123096): Upcoming Dividend Ex-Date Set for June 3, 2026 - AD HOC NEWS
Richter Gedeon Nyrt. Stock (HU0000123096): Upcoming Dividend Ex-Date Set for June 3, 2026 AD HOC NEWS
Applications Open for the 2026 Semmelweis–Richter Journalism Award - Semmelweis Egyetem
Applications Open for the 2026 Semmelweis–Richter Journalism Award Semmelweis Egyetem
Richter Expands Gynecology Portfolio with Major U.S. Acquisition - Hungary Today
Richter Expands Gynecology Portfolio with Major U.S. Acquisition Hungary Today
Showing 6 of 7 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Transdermal estradiol spray in Nordic menopausal women: real-world patient outcomes.
Comparison between the in-bag morcellation techniques during laparoscopic myomectomy or hysterectomy: a systematic review and network meta-analysis.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo